Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.

Go online to PeerView.com/RQP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses emerging treatment options for patients with amyotrophic lateral sclerosis. Upon completion of this CE activity, participants will be able to: Evaluate the mechanisms of action, efficacy, and safety of emerging ALS therapies, Identify the potential impact of emerging therapies on genetic testing and treatment guidelines in ALS, Discuss opportunities with patients to participate in clinical trials.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

Go online to PeerView.com/ETX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in sleep medicine discusses recent guidelines and evidence presented at the SLEEP 2021, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, on the pharmacologic management of idiopathic hypersomnia (IH). Upon completion of this accredited CE activity, participants should be better able to: Employ currently recommended approaches and available assessment tools to identify and differentially diagnose patients with IH, Incorporate the latest guideline recommendations and evidence for approved and emerging pharmacotherapies to optimize the management of patients with IH, Evaluate the clinical potential of recent advances in the pharmacologic treatment of patients with IH.

Go online to PeerView.com/AFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Pompe disease discusses the presentation of infantile- and late-onset Pompe disease, as well as treatment via enzyme replacement therapy. Upon completion of this accredited CE activity, participants should be better able to: Employ recommended assessments, including newborn screening (NBS), clinical presentation, and appropriate tests, to diagnose Pompe disease in a timely manner, Apply current recommendations and evidence regarding use of enzyme replacement therapy in the interdisciplinary management of Pompe disease, Recognize the potential role of emerging enzyme-replacement therapies in the treatment of Pompe disease.

Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.

Go online to PeerView.com/BPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the management of motor complications in Parkinson’s disease. Upon completion of this accredited CE activity, participants should be better able to: Identify the need to adjust treatment for “off” episodes in Parkinson’s disease through symptom and therapy assessment and clear communication with patients and/or caregivers, Interpret evidence regarding on-demand treatment options and their role in the management of “off” episodes in Parkinson’s disease, Apply on-demand treatment options, based on current evidence, in the personalized management of “off” episodes in Parkinson’s disease.

Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.

Go online to PeerView.com/WEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss treatment with B-cell therapies in patients with multiple sclerosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Recognize the similarities and differences between anti-CD20 monoclonal antibodies available for the treatment of relapsing forms of MS, Analyze available evidence on investigational B-cell–targeting therapies, Employ a patient-centered approach to treatment selection for patients with MS based on their disease activity, treatment preferences and goals, and therapeutic options.